This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.
Chairman of the Board
Udo J. Vetter has served as a member of ITM’s supervisory board since 2006 and has been its chairman since 2007. As one of the founding fathers of the company, he has made significant contribution to the establishment and development of ITM as a vertically integrated biopharmaceutical company through his broad pharmaceutical expertise and strategic advice.
Since 1987, Mr Vetter has held various senior management positions at the Vetter Group. Since 2008 he is chairman of the advisory board of Vetter Pharma-Fertigung GmbH & Co. KG. In 2003 Mr. Vetter established the investment company UV-Cap GmbH & Co. KG and serves as its managing director to present. From 1983 to 1992 he was vice president for licensing and production at Martec Inc. and president of Vetter Pharma-Turm Inc. Previously he worked for five years as a pharmacist at the pharmaceutical company Schering-Plough Corp. (now Merck & Co Inc.) and set up production facilities in Puerto Rico.
Mr. Vetter is a member of the supervisory board of Gerresheimer AG and of the expert association ISPE (International Society of Pharmaceutical Engineers). He is also a member of the board of directors at Gland Pharma Ltd., India. He was chairman of the university council of the University Albstadt-Sigmaringen until 2018, receiving the title Honorary Senator from the educational institution in the same year. Since 2019, he is president of European Family Businesses (EFB). He obtained a degree in Clinical Pharmacy at the University of Washington in Seattle.
Vice Chairman of the Board
Steffen Schuster served as Chief Executive Officer of ITM from December 2011 to August 2024. During his tenure, he expanded the development and production of medical radioisotopes, transforming ITM from a pure radioisotope manufacturer into a global biotechnology and radiopharmaceutical leader. He also established key strategic partnerships, secured significant financing, and oversaw the opening of new sites in Germany and the United States.
Prior to his work at ITM, Mr. Schuster was a General Partner at TVM Capital. Before that, he served as the Chief Financial Officer of the publicly listed cycos AG. Earlier in his career, Mr. Schuster worked for the Siemens Network Division, where he held a variety of leading roles including international M&A as well as co-founder of the Mustang Ventures fund with headquarters in Silicon Valley where he acted as Managing Director and Investment Partner.
Mr. Schuster holds a Master’s Degree in Economics (Dipl.-Kfm.) from the University of Saarbrücken, Germany.
Oliver Buck is the founder of ITM. From 2005 to 2011, Mr. Buck devoted his time and expertise to the initial build-up of ITM as its chief executive officer and subsequently has served as a member of ITM’s supervisory board and as a senior advisor to the company since 2012. His main focus in this function has been in supporting the company in the expansion of its strategic, technological and global footprint.
He holds a graduate degree (Dipl.-Phys.) in theoretical physics from the Technical University of Munich (TUM) and is an accomplished serial entrepreneur with a track record of pioneering work across a range of technologies and industries. Since 2002 his main focus has been in the life-science and radiopharmaceutical space.
Oliver Buck is an alumnus of the American Council on Germany (ACG)/Atlantikbrücke’s “Young Leaders Program”, of the German Federal Academy for Security Policies “(BakS) Core Seminar” and of the Singularity Universities (SU) Executive Program. He also is a co-founder of Global Bridges e.V. and a co-founder and member of the Board of Trustees of the International Centers for Precision Oncology (ICPO) Foundation.
Michael joined the supervisory board in May 2019. Michael is founder and chairman of Portland Holdings, a privately held investment company headquartered in Burlington, Ontario, Canada. The company is committed to investing in businesses active in strong, long-term growth industries that also seek to improve the social well-being of the communities in which they operate. The philosophy of Michael Lee-Chin and Portland Holdings is to “do well and do good” – building strong businesses that are giving back to society. For his entrepreneurial and philanthropic work, Michael has received numerous awards and honors.
Manuel holds an MA in finance from the University of St. Gallen and the Fudan University in Shanghai. He is a CFA and also a CAIA charterholder. After having worked for The Boston Consulting Group and a private equity firm, Manuel structured and now runs the investments of Dr Uli Sigg, the former Swiss ambassador to China. Manuel sits on numerous boards of directors of technology and financial services companies.
Tadd joined the supervisory board in June 2021. He is the Founder and Managing Partner of Petrichor Healthcare Capital Management, a private equity firm focused on the healthcare sector. Tadd was formerly a Managing Director at OrbiMed Advisors and Vice President at Fortress Investment Group. Tadd sits on numerous boards of directors of life sciences companies. He holds an A.B. (Artium Baccalaureus) in Biology from Princeton University.